Current Report Filing (8-k)
February 13 2020 - 04:40PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF
1934
Date
of Report (Date of earliest event reported): February 11, 2020
VistaGen Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
NEVADA
|
000-54014
|
20-5093315
|
(State or other jurisdiction of
incorporation)
|
(Commission File Number)
|
(IRS Employer Identification
Number)
|
343 Allerton Ave.
South San Francisco, California
94090
|
(Address of principal executive
offices)
|
(650)
577-3600
(Registrant’s telephone number, including area
code)
Not Applicable
(Former name or former address, if changed since last
report)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the
following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a -12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d -2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e -4(c))
Securities
registered pursuant to Section 12(b) of the
Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par
value $0.001 per share
|
VTGN
|
Nasdaq Capital
Market
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (17 CFR
230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17
CFR 240.12b-2)
Emerging Growth Company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the
Exchange Act ☐
Item
2.02 Results of Operations and Financial
Condition.
On February 13, 2020, VistaGen Therapeutics, Inc.
(the “Company”) issued a press release to announce the
Company’s financial results for its fiscal year 2020 third
quarter ended December 31, 2019. A copy of the press release is
attached to this Current Report on Form 8-K as Exhibit
99.1.
Item 8.01 Other Events.
On
February 11, 2020, the Company announced positive preclinical data of
AV-101, the Company’s oral NMDAR (N-methyl-D-aspartate
receptor) antagonist prodrug, administered in combination with
probenecid. The new preclinical data suggest that there is a
substantially increased brain concentration of AV-101 and its
active metabolite, 7-chlorokynurenic acid (7-Cl-KYNA), when AV-101
is given together with probenecid. A copy of the press release is
attached to this Current Report on Form 8-K as Exhibit
99.2.
Item 9.01 Exhibits.
(d)
Exhibits
Exhibit Number
|
|
Description
|
|
|
Press
Release issued by VistaGen Therapeutics, Inc., dated February 13,
2020.
|
|
|
Press
Release issued by VistaGen Therapeutics, Inc., dated February 11,
2020.
|
Signatures
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
VistaGen Therapeutics,
Inc.
|
|
|
|
Date: February 13,
2020
|
By:
|
/s/
Shawn K.
Singh
|
|
|
Shawn K.
Singh
Chief Executive
Officer
|
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Feb 2024 to Mar 2024
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Mar 2023 to Mar 2024